LeonaBio (LONA) Operating Expenses (2019 - 2026)
LeonaBio (LONA) posted quarterly Operating Expenses of $17.2 million for Q1 2026, up 815.64% year-over-year from $1.9 million in Q1 2025, and down 82.23% quarter-over-quarter from $96.9 million in Q4 2025.
LeonaBio (LONA) Operating Expenses (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Operating Expenses for 8 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 815.64% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $122.8 million (down 2.76% YoY), while the FY2025 annual figure was $102.3 million, up 1.35% from the prior year.
- Operating Expenses eased to $17.2 million in Q1 2026 per LONA's latest filing, from $96.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $96.9 million in Q4 2025 and bottomed at $1.8 million in Q2 2025.
- Historically, Operating Expenses has averaged $28.3 million across 5 years, with a median of $24.1 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Expenses tumbled 90.19% — and 2026, when it jumped 815.64%.
- LeonaBio's Operating Expenses stood at $32.9 million in 2022, then retreated by 11.88% to $29.0 million in 2023, then surged by 214.87% to $91.4 million in 2024, then advanced by 6.06% to $96.9 million in 2025, then slumped by 82.23% to $17.2 million in 2026.
- Business Quant data shows LONA's Operating Expenses at $17.2 million in Q1 2026, $96.9 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | 19.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.21 Mn |
| Dec 31, 2025 | 96.89 Mn |
| Sep 30, 2025 | 6.87 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 91.36 Mn |
| Sep 30, 2024 | 29.62 Mn |
| Jun 30, 2024 | 3.45 Mn |
| Mar 31, 2024 | 2.92 Mn |
| Dec 31, 2023 | 29.01 Mn |
| Sep 30, 2023 | 35.04 Mn |
| Jun 30, 2023 | 31.64 Mn |
| Mar 31, 2023 | 29.77 Mn |
| Dec 31, 2022 | 32.93 Mn |
| Sep 30, 2022 | 24.13 Mn |
| Jun 30, 2022 | 23.57 Mn |
| Mar 31, 2022 | 23.39 Mn |
| Dec 31, 2021 | 18.78 Mn |
| Sep 30, 2021 | 17.83 Mn |
| Jun 30, 2021 | 16.64 Mn |